Agilent Technologies Inc vs Wahed FTSE USA Shariah ETF — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.00B), while Wahed FTSE USA Shariah ETF trades at $73.25. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | HLAL | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Sector/Thematic |
52-Week High | $157.20 | $73.60 |
52-Week Low | $110.24 | $55.52 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
HLAL stock trades at $73.14, up 0.71% with strong bullish technical signals from moving averages. The stock shows positive momentum with key indicators suggesting upward trend continuation. Recent dividend announcement of $0.02 scheduled for June 2026 provides long-term income potential.
The stock presents a bullish technical outlook with fundamental analysis limited by incomplete financial data. Investment opportunity lies in the strong technical momentum, though risks include potential overbought conditions and lack of current financial metrics for comprehensive valuation assessment.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →